Information  X 
Enter a valid email address

Company Name matching 'MorphoSys AG'

Date
Time Source
Company
Announcement
03 Aug 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
01 Aug 2020 12:35 am EQS Factsheet MorphoSys AG (0FAU) Ad hoc: FDA Approves Monjuvi(R) (tafasitamab-cxix) in Combination with Lenalidomide for the Treatment of Adult Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
31 Jul 2020 9:00 am EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
14 Jul 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
07 Jul 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
02 Jul 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  2:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
26 Jun 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
25 Jun 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
24 Jun 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
22 Jun 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
18 Jun 2020 3:05 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
15 Jun 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
09 Jun 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  2:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
05 Jun 2020 2:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
04 Jun 2020 2:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
28 May 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  11:36 am EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
07 May 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
06 May 2020 9:01 pm EQS Factsheet MorphoSys AG (0FAU) MorphoSys Reports First Quarter 2020 Results
05 May 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
04 May 2020 3:48 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
30 Apr 2020 12:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
29 Apr 2020 12:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
28 Apr 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
23 Apr 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
21 Apr 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
17 Apr 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
27 Mar 2020 12:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
23 Mar 2020 3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
  3:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
19 Mar 2020 8:00 am EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
13 Mar 2020 5:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
05 Mar 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
03 Mar 2020 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
31 Jan 2020 2:22 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
13 Jan 2020 6:32 am EQS Factsheet MorphoSys AG (0FAU) Ad hoc: MorphoSys and Incyte Sign Global Collaboration and License Agreement, including U.S. Co-Commercialization and Ex-U.S. Commercialization Rights, for Tafasitamab
16 Dec 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
12 Dec 2019 4:03 pm EQS Factsheet MorphoSys AG (0FAU) Preliminary announcement of the publication of quarterly reports and quarterly/interim statements
  4:02 pm EQS Factsheet MorphoSys AG (0FAU) Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
11 Dec 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
05 Dec 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
03 Dec 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
29 Nov 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 41 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
20 Nov 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
18 Nov 2019 3:31 pm EQS Factsheet MorphoSys AG (0FAU) Ad hoc: MorphoSys' tafasitamab B-MIND DLBCL study successfully passed futility analysis
11 Nov 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
06 Nov 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
29 Oct 2019 6:38 pm EQS Factsheet MorphoSys AG (0FAU) Ad hoc: Primary Endpoint met in Real-World Data Study Demonstrating Clinical Superiority of the Combination of Tafasitamab and Lenalidomide compared to Lenalidomide alone
28 Oct 2019 8:44 pm EQS Factsheet MorphoSys AG (0FAU) Ad hoc: MOR106 Clinical Development in Atopic Dermatitis Stopped for Futility
15 Oct 2019 4:00 pm EQS Factsheet MorphoSys AG (0FAU) Correction of a release from 11/10/2019 according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
14 Oct 2019 12:01 pm EQS Factsheet MorphoSys AG (0FAU) MorphoSys and I-Mab Biopharma Announce IND Clearance to Initiate Clinical Trials of MOR202/TJ202 for the Treatment of Multiple Myeloma in Mainland China
15 Nov 2016 10:34 pm GNW Factsheet MorphoSys AG (0FAU) Ad hoc: MorphoSys Raises EUR 115 million in Private Placement
  4:55 pm GNW Factsheet MorphoSys AG (0FAU) Ad hoc: MorphoSys to Raise Capital via a Private Placement of New Shares
01 Oct 2016 10:43 am GNW Factsheet MorphoSys AG (0FAU) Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis


Company Announcements Archive »

 
Headlines
Top categories
Company finder
Forthcoming announcements

a d v e r t i s e m e n t